Medical news today: Saturday, October 31, 2026
Congo Ebola deaths exceed 5,000 as healthcare costs trouble older Americans and new diagnostics advance
Get tomorrow's issue in your inbox.
- 01
Congo Ebola outbreak passes 5,000 deaths as cases spread across the region
Source: Associated Press
Congolese health ministry data cited by AP show 10,351 people infected and 5,026 deaths in the ongoing Bundibugyo Ebola outbreak. Cases have also been recorded in neighboring and other African countries. Health workers face contact-tracing gaps, attacks and resource shortages.
Why it mattersThe spread underscores the need for coordinated case detection, infection prevention and support for responders. Unlike the Zaire Ebola virus, the Bundibugyo virus has no approved specific vaccine or treatment. More on Approvals & regulatory →
- 02
Older US adults worry about Medicare costs and medication affordability ahead of elections
Source: Associated Press
AP reports that older US voters are closely watching changes to Medicare premiums, drug coverage and insurer participation as healthcare costs strain household budgets. Caregiving expenses and skipped medication due to cost remain prominent concerns.
Why it mattersCoverage and affordability can determine whether older patients maintain treatment; changes in benefits and formularies warrant careful review before enrollment decisions.
- 03
Investigational vaginal swab could reduce the need for invasive endometrial biopsies
Source: Medical Xpress / HealthDay
A vaginal swab test under investigation at 16 US sites aims to detect molecular signals from endometrial cancer in symptomatic women. The approach is still in clinical evaluation; positive results and persistent symptoms require appropriate medical follow-up.
Why it mattersA less-invasive first-line test could improve the experience of assessing postmenopausal bleeding, but accuracy, independent validation and follow-up protocols must be established before broad use. More on Oncology →
- 04
Lilly reports retatrutide outperformed Ozempic 2 mg in a phase 3 diabetes trial
Source: Eli Lilly
The company said participants on retatrutide reduced HbA1c by about 2.2 percentage points and body weight by 19.5% to 20.9% after 80 weeks, versus 1.8 points and 9.4% on semaglutide 2 mg. These are topline company-reported results, not an approval decision.
Why it mattersThe results may influence future diabetes and obesity treatment development if confirmed by full peer-reviewed data and regulators. Gastrointestinal side effects and discontinuation rates remain relevant to benefit-risk assessment. More on Approvals & regulatory →
- 05
Phase 3 study finds retatrutide reduced sleep-apnea events in patients with obesity
Source: New England Journal of Medicine
Two randomized phase 3 trials published in NEJM found that investigational retatrutide reduced the apnea-hypopnea index more than placebo over 80 weeks in adults with moderate-to-severe obstructive sleep apnea and elevated BMI.
Why it mattersThe findings suggest potential benefits beyond weight loss, but retatrutide remains investigational, and patients should not replace established apnea therapies based on these results alone. More on Obesity & metabolic →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
